To the full analysis
Adaptive Biotechnologies stock: growth
ADPTAdaptive Biotechnologies reported $276.98M in revenue for fiscal 2025, up 54.8% on the prior year, up 23% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
28%
per year from 2017 to 2025, per share 22.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 23.0% | 28.0% |
| Revenue per share | 19.5% | 22.3% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $38.45M | −$42.83M | −$37.36M |
| 2018 | $55.66M | −$46.45M | −$38.58M |
| 2019 | $85.07M | −$68.61M | $194.2M |
| 2020 | $98.38M | −$146.23M | −$168.49M |
| 2021 | $154.34M | −$207.28M | −$254.47M |
| 2022 | $185.31M | −$200.19M | −$200.29M |
| 2023 | $170.28M | −$225.25M | −$167.02M |
| 2024 | $178.96M | −$159.49M | −$98.88M |
| 2025 | $276.98M | −$59.5M | −$48.95M |
Revenue by segment
How Adaptive Biotechnologies Corporation makes its money and how that has shifted. Names are as the company reports them.
- Sequencing Revenue$78.9M51%
- Development Support Revenue$65.4M42%
- Development Revenue Regulatory Milestones$10.0M6%
The company split earlier years differently. A history would not be comparable, so only 2021 is shown.
Figures as a table
| 2021 | Share 2021 | |
|---|---|---|
| Sequencing Revenue | $78.9M | 51.1% |
| Development Support Revenue | $65.45M | 42.4% |
| Development Revenue Regulatory Milestones | $10M | 6.5% |
| Total revenue | $154.34M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 21 Feb 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.